Abstract
Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 598-603 |
| Number of pages | 6 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 18 |
| Issue number | 4 |
| State | Published - 1980 |
| Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice'. Together they form a unique fingerprint.
Cite this
Shannon, W. M., Arnett, G., Schabel, F. M., North, T. W., & Cohen, S. S. (1980). Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice. Antimicrobial Agents and Chemotherapy, 18(4), 598-603.